Next revolution in the molecular theranostics of infectious diseases: Microfabricated systems for personalized medicine

Expert Review of Molecular Diagnostics

Volumn 6, Issue 3, 2006, Pages 433-450

  Bissonnette, Luc ^a,b   Bergeron, Michel G ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Infectious diseases; Microarray; Microfabrication; Microfluidics; Molecular theranostics; Personalized medicine; Pharmacogenomics

Indexed keywords

APTAMER; CYTOCHROME; CYTOCHROME P450; NUCLEIC ACID; DRUG;

CYTOLYSIS; DRUG METABOLISM; ELECTRODE; GOLD STANDARD; HUMAN; HYBRIDIZATION; IMMUNOGENETICS; INFECTION; KINETICS; METHODOLOGY; MICROARRAY ANALYSIS; MOLECULAR BEACON; OUTCOME ASSESSMENT; PATIENT CARE; PHARMACOGENOMICS; PROTEIN MICROARRAY; QUALITY CONTROL; RESPIRATORY SYSTEM; REVIEW; WORLD HEALTH ORGANIZATION; CAPILLARY ELECTROPHORESIS; COMMUNICABLE DISEASE; DIAGNOSTIC PROCEDURE; DNA MICROARRAY; DRUG DESIGN; GENETICS; HEALTH SERVICE; MEDICAL GENETICS; METABOLISM; PHARMACOGENETICS;

COMMUNICABLE DISEASES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DESIGN; ELECTROPHORESIS, CAPILLARY; GENETICS, MEDICAL; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PERSONAL HEALTH SERVICES; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS;

EID: 33745959395     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.6.3.433     Document Type: Review

References (184)

1. Cohen ML. Changing patterns of infectious disease. Nature 406(6797), 762-767 (2000).
2. Snell NJC. Examining unmet needs in infectious disease. Drug Discov. Today 8(1), 22-30 (2003).
3. Morens DM, Folkers GK, Fauci AS. The challenge of emerging and re-emerging infectious diseases. Nature 430(6996), 242-249 (2004).
4. Fauci AS. Emerging infectious diseases - a clear and present danger to humanity. JAMA 292(15), 1887-1888 (2005).
5. Picard FJ, Bergeron MG. Rapid molecular theranostics in infectious diseases. Drug Discov. Today 7(21) 1092-1100 (2002).
6. Boissinot M, Bergeron MG. Toward rapid real-time molecular diagnostic to guide smart use of antimicrobials. Curr. Opin. Microbiol. 5(5), 478-482 (2002).
7. McGowan JE Jr, Tenover FC. Confronting bacterial resistance in healthcare settings: a crucial role for microbiologists. Nature Rev. Microbiol. 2(3), 251-258 (2004).
8. Versalovic J, Lupski JR. Molecular detection and genotyping of pathogens: more accurate and rapid answers. Trends Microbiol. 10(10 Suppl.), S15-S21 (2002).
9. Fenollar F, Raoult D. Molecular genetic methods for the diagnosis of fastidious microorganisms. APMIS 112(11-12), 785-807 (2004).
10. Mackay IM. Real-time PCR in the microbiology laboratory. Clin. Microbiol. Infect. 10(3), 190-212 (2004).
11. Peters RPH, van Agtmael MA, Danner SA, Savelkoul PHM, Vandenbroucke-Grauls CMJE. New developments in the diagnosis of bloodstream infections. Lancet Infect. Dis. 4(12), 751-760 (2004).
12. Raoult D, Fournier PE, Drancourt M. What does the future hold for clinical microbiology? Nature Rev. Microbiol. 2(2), 151-159 (2004). • Good forecast of the introduction of microarrays in infectious diseases diagnostics.
13. Yang S, Rothman RE. PCR-based diagnostics for infectious diseases: uses, limitations, and future applications in acute-care settings. Lancet Infect. Dis. 4(6), 337-348 (2004). • Historical perspective and diagnostic value of PCR-based diagnostics implementation in clinical laboratories.
14. Mothershed EA, Whitney AM. Nucleic acid-based methods for the detection of bacterial pathogens: present and future considerations for the clinical laboratory. Clin. Chim. Acta 363(1-2), 206-220 (2006). •• Compact overview of nucleic acid-based methods for diagnostics of infectious diseases.
15. Aslanzadeh J. Preventing PCR amplification carryover contamination in a clinical laboratory. Ann. Clin. Lab. Sci. 34(4), 389-396 (2004).
16. Borst A, Box ATA, Fluit AC. False-positive results and contamination in nucleic acid amplification assays: suggestions for a prevent and destroy strategy. Eur. J. Clin. Microbiol. Infect. Dis. 23(4), 289-299 (2004).
17. Sefers S, Pei Z, Tang Y-W. False positives and false negatives encountered in diagnostic molecular microbiology. Rev. Med. Microbiol. 16(2), 59-67 (2005).
18. Fortina P, Surrey S, Kricka LJ. Molecular diagnostics: hurdles for clinical implementation. Trends Mol. Med. 8(6), 264-266 (2002).
19. Ardekani AM, Petricoin EF III, Hackett JL. Molecular diagnostics: an FDA perspective. Expert Rev. Mol. Diagn. 3(2), 129-140 (2003).
20. Bergeron MG, Ke D, Ménard C et al. Rapid detection of group B streptococci in pregnant women at delivery. N. Engl. J. Med. 343(3), 175-179 (2000).
21. Huletsky A, Giroux R, Rossbach V et al. New real-time PCR assay for rapid detection of methicillin-resistant Staphylococcus aureus directly from speciments containing a mixture of staphylococci. J. Clin. Microbiol. 42(5), 1875-1884 (2004).
22. Carrigan SD, Scott G, Tabrizian M. Toward resolving the challenge of sepsis diagnosis. Clin. Chem. 50(8), 1301-1314 (2004).
23. Korppi M. Mixed microbial aetiology of community-acquired pneumonia in children. APMIS 110(7-8), 515-522 (2002).
24. Park DR. The microbiology of ventilator-associated pneumonia. Respir. Care 50(6), 742-765 (2005).
25. Schneede P, Tenke P, Hofstetter AG, Members of the Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). Sexually transmitted diseases (STDs) - a synoptic overview for urologists. Eur. Urol. 44(1), 1-7 (2003).
26. Donovan B. Sexually transmissible infections other than HIV. Lancet 363(9408), 545-556 (2004).
27. Bryant PA, Venter D, Robins-Browne R, Curtis N. Chips with everything: DNA microarrays in infectious diseases. Lancet Infect. Dis. 4(2), 100-111 (2004). • Potential of the microarray format for diagnostics of infectious diseases.
28. Loy A, Bodrossy L. Highly parallel microbial diagnostics using oligonucleotide microarrays. Clin. Chim. Acta 363(1-2), 106-119 (2006). •• Excellent review of microarray technology and associated strategies.
29. Lehmann CA. The future of home testing - implications for traditional laboratories. Clin. Chim. Acta 323(1-2), 31-36 (2002).
30. Holland CA, Kiechle FL. Point-of-care molecular diagnostic systems - past, present and future. Curr. Opin. Microbiol. 8(5), 504-509 (2005). • Introduction to point-of-care molecular diagnostics analyzers.
31. Mabey D, Peeling RW, Ustianowski A, Perkins MD. Diagnostics for the developing world. Nature Rev. Microbiol. 2(3), 231-240 (2004).
32. Daar AS, Thorsteinsdóttir H, Martin DK, Smith AC, Nast S, Singer PA. Top ten biotechnologies for improving health in developing countries. Nature Genet. 32(2), 229-232 (2002). •• Key article illustrating the importance of the diagnostics of infectious diseases.
33. van Ommen GJB, Bakker E, den Dunnen JT. The human genome project and the future of diagnostics, treatment, and prevention. Lancet 354(Suppl. 1), 5-10 (1999).
34. McLeod HL, Evans WE. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu. Rev. Pharmacol. Toxicol. 41, 101-121 (2001).
35. Hiratsuka M, Sasaki T, Mizugaki M. Genetic testing for pharmacogenetics and its clinical application in drug therapy. Clin. Chim. Acta 363(1-2), 177-186 (2006).
36. Ajayi FO, Sun H, Perry J. Adverse drug reactions: a review of relevant factors. J. Clin. Pharmacol. 40(10), 1093-1101 (2000).
37. Suh D-C, Woodall BS, Shin S-K, Hermes-De Santis ER. Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann. Pharmacother. 34(12), 1373-1379 (2000).
38. Goldstein DB, Tate SK, Sisodiya SM. Pharmacogenetics goes genomic. Nature Rev. Genet. 4(12), 937-947 (2003).
39. Lindpaintner K. Pharmacogenetics and the future of medical practice. J. Mol. Med. 81(3), 141-153 (2003). •• Definition of pharmacogenetics and pharmacogenomics.
40. Oscarson M. Pharmacogenetics of drug metabolising enzymes: importance for personalised medicine. Clin. Chem. Lab. Med. 41(4), 573-580 (2003).
41. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 429(6990), 464-468 (2004).
42. Fierz W. Challenge of personalized health care: to what extent is medicine already individualized and what are the future trends? Med. Sci. Monit. 10(5), RA111-RA123 (2004). •• Excellent pivotal article addressing personalized medicine.
43. Higashi MK, Veenstra DL, Kondo LM et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287(13), 1690-1698 (2002).
44. Anzenbacher P, Anzenbacherová E. Cytochromes P450 and metabolism of xenobiotics. Cell. Mol. Life Sci. 58(5-6), 737-747 (2001).
45. Lobstein R, Vecsler M, Kurnik D et al. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9. Clin. Pharmacol. Ther. 77(5), 365-372 (2005).
46. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet. 38(1), 41-57 (2000).
47. Fuhr U. Induction of drug metabolising enzymes. Clin. Pharmacokinet. 38(6), 493-504 (2000).
48. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs. Drugs 61(15), 2163-2175 (2001).
49. Huang S-M, Hall SD, Watkins P et al. Drug interactions with herbal products and grapefruit juice: a conference report. Clin. Pharmacol. Ther. 75(1), 1-12 (2004).
50. Foster BC, Arnason JT, Briggs CJ. Natural health products and drug disposition. Annu. Rev. Pharmacol. Toxicol. 45, 203-226 (2005).
51. Park BK, Kitteringham NR, Maggs JL, Pirmohamed M, Williams DP. The role of metabolic activation in drug-induced hepatotoxicity. Annu. Rev. Pharmacol. Toxicol. 45, 177-202 (2005).
52. Blackwell JM. Genetics and genomics in infectious disease susceptibility. Trends Mol. Med. 7(11), 521-526 (2001).
53. Schröder NWJ, Schumann RR. Single-nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect. Dis. 5(3), 156-164 (2005).
54. Hayney MS. Pharmacogenomics and infectious diseases: impact on drug response and applications to disease management. Am. J. Health Syst. Pharm. 59(17), 1626-1631 (2002).
55. Dean M, Carrington M, O'Brien SJ. Balanced polymorphism selected by genetic versus infectious human disease. Annu. Rev. Genomics Hum. Genet. 3, 263-292 (2002).
56. Blackwell JM, Goswami T, Evans CAW et al. SLC11A1 (formerly NRAMP1) and disease resistance. Cell. Microbiol. 3(12), 773-784 (2001).
57. Ottenhoff THM, Verreck FAW, Lichtenauer-Kaligis EGR, Hoeve MA, Sanal O, van Dissel JT. Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae. Nature Genet. 32(1), 97-105 (2002).
58. van de Vosse E, Hoeve MA, Ottenhoff THM. Human genetics of intracellular infectious diseases: molecular and cellular immunity against mycobacteria and salmonellae. Lancet Infect. Dis. 4(12), 739-749 (2004).
59. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286(5439), 487-491 (1999).
60. Ross JS, Ginsburg GS. Integrating diagnostics and therapeutics: revolutionizing drug discovery and patient care. Drug Discov. Today 7(16), 859-864 (2002).
61. Johnson JA. Pharmacogenetics: potential for individualized drug therapy through genetics. Trends Genet. 19(11), 660-666 (2003).
62. Lesko LJ, Woodcock J. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nature Rev. Drug Discov. 3(9), 763-769 (2004).
63. Kinzig-Schippers, Tomalik-Scharte D, Jetter A et al. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob. Agents Chemother. 49(5), 1733-1738 (2005).
64. Rosen S. Market outlook for IVDs. IVD Technol. 10(7), 39-43 (2004).
65. Ehrnström R. Miniaturization and integration: challenges and breakthroughs in microfluidics. Lab Chip 2(2), 26N-30N (2002).
66. Verpoorte E. Microfluidic chips for clinical and forensic analysis. Electrophoresis 23(5), 677-712 (2002).
67. Felton MJ. CD simplicity. Anal. Chem. 75(13), 302A-306A (2003).
68. Huikko K, Kostiainen R, Kotiaho T. Introduction to micro-analytical systems: bioanalytical and pharmaceutical applications. Eur. J. Pharm. Sci. 20(2), 159-171 (2003).
69. Erickson D, Li D. Integrated microfluidic devices. Anal. Chim. Acta 507(1), 11-26 (2004).
70. Gascoyne P, Satayavivad J, Ruchirawat M. Microfluidic approaches to malaria detection. Acta Trop. 89(3), 357-369 (2004).
71. Gui L, Liu J. Ice valve for a mini/micro flow channel. J. Micromech. Microeng. 14(2), 242-246 (2004).
72. Lee SJ, Lee SY. Micro total analysis system (μ-TAS) in biotechnology. Appl. Microbiol. Biotechnol. 64(3), 289-299 (2004).
73. Vilkner T, Janasek D, Manz A. Micro total analysis systems. Recent developments. Anal. Chem. 76(12), 3373-3386 (2004).
74. Chen Z, Wang J, Qian S, Bau HH. Thermally-actuated, phase change flow control for microfluidic systems. Lab Chip 5(11), 1277-1285 (2005).
75. Kricka LJ, Park JY, Li SFY, Fortina P. Miniaturized detection technology in molecular diagnostics. Expert Rev. Mol. Diagn. 5(4), 549-559 (2005). •• Excellent overview of micro- and nanotechnologies applied to molecular diagnostics.
76. Furdui VI, Harrison DJ. Immunomagnetic T cell capture from blood for PCR analysis using microfluidic systems. Lab Chip 4(6), 614-618 (2004).
77. de Mello AJ, Beard N. Dealing with 'real' samples: sample pre-treatment in microfluidic systems. Lab Chip 3(1), 11N-19N (2003).
78. Gu H, Ho P-L, Tsang KWT, Wang L, Xu B. Using biofunctional magnetic nanoparticles to capture vancomycin-resistant enterococci and other Gram-positive bacteria at ultralow concentration. J. Am. Chem. Soc. 125(51), 15702-15703 (2003).
79. Huang T, Geng T, Sturgis J et al. Lysozyme for capture of microorganisms on protein biochips. Enzyme Microb. Technol. 33(7), 958-966 (2003).
80. Kist TBL, Mandaji M. Separation of biomolecules using electrophoresis and nanostructures. Electrophoresis 25(21-22), 3492-3497.
81. Hofmann O, Murray K, Wilkinson A-S, Cox T, Manz A. Laser induced disruption of bacterial spores on a microchip. Lab Chip 5(4), 374-377 (2005).
82. Kim J, Jang SH, Jia G, Zoval JV, Da Silva NA, Madou MJ. Cell lysis on a microfluidic CD (compact disc). Lab Chip 4(5), 516-522 (2004).
83. Breadmore MC, Wolfe KA, Arcibal IG et al. Microchip-based purification of DNA from biological samples. Anal. Chem. 75(8), 1880-1886 (2003).
84. Chung Y-C, Jan M-S, Lin Y-C, Lin J-H, Cheng W-C, Fan C-Y. Microfluidic chip for high efficiency DNA extraction. Lab Chip 4(2), 141-147 (2004).
85. Peterson DS. Solid supports for micro analytical systems. Lab Chip 5(2), 132-139 (2005).
86. Atencia J, Beebe DJ. Controlled microfluidic interfaces. Nature 437(7059), 648-655 (2005).
87. Hesse J, Wechselberger C, Sonnleitner M, Schindler H, Schultz GJ. Single-molecule reader for proteomics and genomics. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 782(1-2), 127-135 (2002).
88. Chen Z, Qian S, Abrams WR, Malamud D, Bau HH. Thermosiphon-based PCR reactor: experiment and modeling. Anal. Chem. 76(13), 3707-3715 (2004).
89. Hashimoto M, Chen P-C, Mitchell MW, Nikitopoulos DE, Soper SA, Murphy MC. Rapid PCR in a continuous flow device. Lab Chip 4(6), 638-645 (2004).
90. Lee D-S, Park SH, Yang H et al. Bulk-micromachined submicroliter-volume PCR chip with very rapid thermal response and low power consumption. Lab Chip 4(4), 401-407 (2004).
91. Lee TM-H, Carles MC, Hsing I-M. Microfabricated PCR-electrochemical device for simultaneous DNA amplification and detection. Lab Chip 3(2), 100-105 (2003).
92. Kricka LJ, Wilding P. Microchip PCR. Anal. Bioanal. Chem. 377(5), 820-825 (2003).
93. Landers JP. Molecular diagnostics on electrophoretic microchips. Anal. Chem. 75(12), 2919-2927 (2003).
94. Qin J, Fung Y, Lin B. DNA diagnosis by capillary electrophoresis and microfabricated electrophoretic devices. Expert Rev. Mol. Diagn. 3(3), 387-394 (2003).
95. Lagally ET, Scherer JR, Blazej RG et al. Integrated portable genetic analysis microsystem for pathogen/infectious disease detection. Anal. Chem. 76(11), 3162-3170 (2004).
96. Liu RH, Yang J, Lenigk R, Bonanno J, Grodzinski P. Self-contained, fully integrated biochip for sample preparation, polymerase chain reaction amplification, and DNA microarray detection. Anal. Chem. 76(7), 1824-1831 (2004).
97. Obeid PJ, Christopoulos TK. Microfabricated systems for nucleic acid analysis. Crit. Rev. Clin. Lab. Sci. 41(5-6), 429-465 (2004).
98. Hashimoto M, Hupert ML, Murphy MC, Soper SA, Cheng Y-W, Barany F. Ligase detection reaction/hybridization assays using three-dimensional microfluidic networks for the detection of low-abundant DNA point mutations. Anal. Chem. 77(10), 3243-3255 (2005).
99. Gulliksen A, Solli L, Karlsen F et al. Real-time nucleic acid sequence-based amplification in nanoliter volumes. Anal. Chem. 76(1), 9-14 (2004).
100. Vincent M, Xu Y, Kong H. Helicase-dependent isothermal DNA amplification. EMBO Rep. 5(8), 1-6 (2004).
101. Krishnan M, Ugaz VM, Burns MA. PCR in a Rayleigh-Bénard convection cell. Science 298(5594), 793 (2002).
102. Simon R. Using DNA microarrays for diagnostic and prognostic prediction. Expert Rev. Mol. Diagn. 3(5), 587-595 (2003).
103. Petricoin EF III, Hackett JL, Lesko LJ et al. Medical applications of microarray technologies: a regulatory science perspective. Nature Genet. 32(Suppl.), 474-479 (2002).
104. Call DR. Challenges and opportunities for pathogen detection using DNA microarrays. Crit. Rev. Microbiol. 31(2), 91-99 (2005).
105. Reyes DR, Iossifidis D, Auroux P-A, Manz A. Micro total analysis systems. 1. Introduction, theory, and technology. Anal. Chem. 74(12), 2623-2636 (2002).
106. Zhao DS, Roy B, McCormick MT, KuhrWG, Brazill SA. Rapid fabrication of a poly(dimethylsiloxane) microfluidic capillary electrophoresis system utilizing high precision machining. Lab Chip 3(2), 93-99 (2003).
107. Fiorini GS, Chiu DT. Disposable microfluidic devices: fabrication, function, and application. Biotechniques 38(3), 429-446 (2005). •• Very good technical review of microfabrication and microfluidic technologies.
108. Noerholm M, Bruus H, Jakobsen MH, Telleman P, Ramsing NB. Polymer microfluidic chip for online monitoring of microarray hybridizations. Lab Chip 4(1), 28-37 (2004).
109. Erickson D, Liu X, Venditti R, Li D, Krull UJ. Electrokinetically based approach for single-nucleotide polymorphism discrimination using a microfluidic device. Anal. Chem. 77(13), 4000-4007 (2005).
110. Peytavi R, Raymond FR, Gagné D et al. Microfluidic device for rapid (<15 min) automated microarray hybridization. Clin. Chem. 51(10), 1836-1844 (2005).
111. Lenigk R, Liu RH, Athavale M et al. Plastic biochannel hybridization devices: a new concept for microfluidic DNA arrays. Anal. Biochem. 311(1), 40-49 (2002).
112. Chung Y-C, Lin Y-C, Shiu M-Z, Chang W-NT. Microfluidic chip for fast nucleic hybridization. Lab Chip 3(4), 228-233 (2003).
113. Gurtner C, Tu E, Jamshidi N et al. Microelectronic array devices and techniques for electric field enhanced DNA hybridization in low-conductance buffers. Electrophoresis 23(10), 1543-1550 (2002).
114. Barlaan EA, Sugimori M, Furukawa S, Takeuchi K. Electronic microarray analysis of 16S rDNA amplicons for bacterial detection. J. Biotechnol. 115(1), 11-21 (2005).
115. Liu RH, Lenigk R, Druyor-Sanchez RL, Yang J, Grodzinski P. Hybridization enhancement using cavitation microstreaming. Anal. Chem. 75(8), 1911-1917 (2003).
116. Dunbar SA, Vander Zee CA, Oliver KG, Karem KL, Jacobson JW. Quantitative, multiplexed detection of bacterial pathogens: DNA and protein application of the Luminex LabMAP™ system. J. Microbiol. Meth. 53(2), 245-252 (2003).
117. Kessler N, Ferraris O, Palmer K, Marsh W, Steel A. Use of the DNA Flow-Thru Chip, a three-dimensional biochip, for typing and subtyping of influenza viruses. J. Clin. Microbiol. 42(5), 2173-2185 (2004).
118. Shendure J, Mitra RD, Varma C, Church GM. Advanced sequencing technologies: methods and goals. Nature Rev. Genet. 5(5), 335-344 (2004).
119. Ugaz VM, Elms RD, Lo RC, Shaikh FA, Burns MA. Microfabricated electrophoresis systems for DNA sequencing and genotyping applications: current technology and future directions. Phil. Trans. R. Soc. Lond. A 362(1818), 1105-1129 (2004).
120. Tegenfeldt JO, Prinz C, Cao H et al. Micro- and nanofluidics for DNA analysis. Anal. Bioanal. Chem. 378(7), 1678-1692 (2004).
121. Grow AE, Wood LL, Claycomb JL, Thompson PA. New biochip technology for label-free detection of pathogens and their toxins. J. Microbiol. Meth. 53(2), 221-233 (2003).
122. Guiducci C, Stagni C, Zuccheri G et al. DNA detection by integrable electronics. Biosens. Bioelectron. 19(8), 781-787 (2004).
123. Uslu F, Ingebrandt S, Mayer D, Böcker-Meffert S, Odenthal M, Offenhausser A. Labelfree fully electronic nucleic acid detection system based on a field-effect transistor device. Biosens. Bioelectron. 19(12), 1723-1731 (2004).
124. Davis F, Higson SPJ. Structured thin films as functional components within biosensors. Biosens. Bioelectron. 21(1), 1-20 (2005).
125. Homola J, Vaisocherová H, Dostálek J, Piliarik M. Multi-analyte surface plasmon resonance biosensing. Methods 37(1), 26-36 (2005).
126. Doré K, Dubus S, Ho H-A et al. Fluorescent polymeric transducer for the rapid, simple, and specific detection of nucleic acids at the zeptomole level. J. Am. Chem. Soc. 126(13), 4240-4244 (2004).
127. Ho HA, Leclerc M. Optical sensors based on hybrid aptamer/conjugated polymer complexes. J. Am. Chem. Soc. 126(5), 1384-1387 (2004).
128. Liu B, Bazan GC. Methods for strandjspecific DNA detection with cationic conjugated polymers suitable for incorporation into DNA chips and microarrays. Proc. Natl Acad. Sci. USA 102(3), 589-594 (2005).
129. Raymond FR, Ho H-A, Peytavi R et al. Detection of target DNA using fluorescent cationic polymer and peptide nucleic acid probes on solid support. BMC Biotechnol. 5, 10 (2005).
130. Ho HA, Doré K, Boissinot M et al. Direct molecular detection of nucleic acids by fluorescence signal amplification. J. Am. Chem. Soc. 127(36), 12673-12676 (2005).
131. Hansen KM, Thundat T. Microcantilever biosensors. Methods 37(1), 57-64 (2005).
132. Tian F, Hansen KM, Ferrell TL, Thundat T. Dynamic microcantilever sensors for discerning biomolecular interactions. Anal. Chem. 77(6), 1601-1606 (2005).
133. Zhou D, Sinniah K, Abell C, Rayment T. Label-free detection of DNA hybridization at the nanoscale: a highly sensitive and selective approach using atomic-force microscopy. Angew. Chem. Int. Ed. 42(40), 4934-4937 (2003).
134. Jain KK. Nanotechnology in clinical laboratory diagnostics. Clin. Chim. Acta 358(1-2), 37-54 (2005). • Relatively complete overview of nanotechnologies that are amenable to clinical diagnostics.
135. Bange A, Halsall HB, Heineman WR. Microfluidic immunosensor systems. Biosens. Bioelectron. 20(12), 2488-2503 (2005).
136. Taitt CR, Golden JP, Shubin YS et al. A portable array biosensor for detecting multiple analytes in complex samples. Microb. Ecol. 47(2), 175-185 (2004).
137. Espina V, Woohouse EC, Wulfkuhle J, Asmussen HD, Petricoin EF III, Liotta LA. Protein microarray detection strategies: focus on direct detection technologies. J. Immunol. Meth. 290(1-2), 121-133 (2004).
138. Krska R, Janotta M. Technology and applications of protein microarrays. Anal. Bioanal. Chem. 379(3), 338-340 (2004).
139. Bertone B, Snyder M. Advances in functional protein microarray technology. FEBS J. 272(21), 5400-5411 (2005).
140. Yuk JS, Ha K-S. Proteomic applications of surface plasmon resonance biosensors: analysis of protein arrays. Exp. Mol. Med. 37(1), 1-10 (2005).
141. O'Sullivan CK. Aptasensors - the future of biosensing? Anal. Bioanal. Chem. 372(1), 44-48 (2002).
142. Jona G, Snyder M. Recent developments in analytical and functional protein microarrays. Curr. Opin. Mol. Therap. 5(3), 271-277 (2003).
143. Tombelli S, Minunni M, Mascini M. Analytical applications of aptamers. Biosens. Bioelectron. 20(12), 2424-2434 (2005)
144. von Lode P. Point-of-care immunotesting: approaching the analytical performance of central laboratory methods. Clin. Biochem. 38(7), 591-606 (2005).
145. Figeys D. Adapting arrays and lab-on-a-chip technology for proteomics. Proteomics 2(4), 373-382 (2002).
146. Lai S, Wang S, Luo J, Lee J, Yang S-T, Madou MJ. Design of a compact disk-like microfluidic platform for enzyme-linked immunosorbent assay. Anal. Chem. 76(7), 1832-1837 (2004).
147. Lin FYH, Sabri M, Erickson D, Alizeraie J, Li D, Sherman PM. Development of a novel microfluidic immunoassay for the detection of Helicobacter pylori infection. Analyst 129(9), 823-828 (2004).
148. Taitt CR, Anderson GP, Ligler FS. Evanescent wave fluorescence biosensors. Biosens. Bioelectron. 20(12), 2470-2487 (2005).
149. Bock C, Coleman M, Collins B et al. Photoaptamer arrays applied to multiplexed proteomic analysis. Proteomics 4(3), 609-618 (2004).
150. Proske D, Blank M, Buhmann R, Resch A. Aptamers - basic research, drug development, and clinical applications. Appl. Microbiol. Biotechnol. 69(4), 367-374 (2005). •• Excellent review demonstrating the methods of generation of aptamers and their fields of application.
151. Xu D, Xu D, Yu X, Liu Z, He W, Ma Z. Label-free electrochemical detection for aptamer-based array electrodes. Anal. Chem. 77(16), 5107-5113 (2005).
152. Yamamoto-Fujita R, Kumar PKR. Aptamer-derived nucleic acid oligos: applications to develop nucleic acid chips to analyze proteins and small ligands. Anal. Chem. 77(17), 5460-5466 (2005). • Very interesting method for the development of aptamers for flexible analyte detection.
153. Disney MD, Seeberger PH. The use of carbohydrate microarrays to study carbohydrate-cell interactions and to detect pathogens. Chem. Biol. 11(12), 1701-1707 (2004).
154. Mahal LK. Catching bacteria with sugar. Chem. Biol. 11(12), 1602-1604 (2004).
155. Ratner DM, Adams EW, Disney MD, Seeberger PH. Tools for glycomics: mapping interactions of carbohydrates in biological systems. Chembiochem 5(10), 1375-1383 (2004).
156. Pilobello KT, Krishnamoorthy L, Slawek D, Mahal LK. Development of a lectin microarray for the rapid analysis of protein glycopatterns. Chembiochem 6(6), 985-989 (2005).
157. Xu Q, Lam KS. Protein and chemical microarrays - powerful tools for proteomics. J. Biomed. Biotechnol. 2003(5), 257-266 (2003).
158. Sheehan PE, Whitman LJ. Detection limits for nanoscale biosensors. Nano Lett. 5(4), 803-807 (2005).
159. Lee K-B, Kim E-Y, Mirkin CA, Wolinsky SM. The use of nanoarrays for highly sensitive and selective detection of human immunodeficiency virus type 1 in plasma. Nano Lett. 4(10), 1869-1872 (2004).
160. Nettikadan SR, Johnson JC, Vengasandra SG, Muys J, Henderson E. ViriChip: a solid phase assay for detection and identification of viruses by atomic force microscopy. Nanotechnology 15(3), 383-389 (2004).
161. Hessner MJ, Meyer L, Tackes J, Muheisen S, Wang X. Immobilized probe and glass surface chemistry as variables in microarray fabrication. BMC Genomics 5, 53 (2004).
162. Dufva M. Fabrication of high quality microarrays. Biomol. Eng. 22(5-6), 173-184 (2005).
163. Pfaller MA. Molecular approaches to diagnosing and managing infectious diseases: practicality and costs. Emerg. Infect. Dis 7(2), 312-318 (2001).
164. Eggertson L. Vioxx award good news for Canadian lawsuits. CMAJ 173(7), 744 (2005).
165. Frantz S. How to avoid another 'Vioxx'. Nature Rev. Drug Discov. 4(1), 5-7 (2005).
166. Gurwitz D, Weizman A, Rehavi M. Education: teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine. Trends Pharmacol. Sci. 24(3), 122-125 (2003).
167. BD Diagnostics - GeneOhm Sciences, Inc. www.geneohm.com
168. US FDA: FDA clears new lab test for group B Strep in pregnant women www.fda.gov/bbs/topics/ANSWERS/2002/ANS01172.html (Viewed November 2005).
169. US FDA: 510(k) summary: IDA-MRSA™ assay Infectio Diagnostic Inc. - K033415 www.fda.gov/cdrh/pdf3/k033415.pdf (Viewed November 2005).
170. US FDA: New device clearance: Roche AmpliChip Cytochrome P450 Genotyping test and Affymetrix GeneChip Microarray Instrumentation System - K042259 www.fda.gov/cdrh/mda/docs/k042259.html (Viewed November 2005).
171. Jurilab Ltd www.jurilab.com
172. Osmetech plc: Proposed acquisition of Clinical Micro Sensors, Inc. ("CMS") from Motorola, Inc., and Placing http://osmetech.plc.uk/news/ 2005/pr010705.htm (Viewed November 2005).
173. Nanogen: Nanogen gains access to diagnostic markers through investment in Jurilab www.nanogen.com/presscenter/pressreleases/1702 (Viewed November 2005).
174. Association for Molecular Pathology. FDA-cleared/approved molecular diagnostics tests www.amp.org/ID/infectious.htm (Viewed April 2006) •• A website to bookmark for the surveillance of US FDA-approved molecular tests.
175. Åmic AB www.4castchip.se (Viewed April 2006)
176. Luminex Corp. www.luminexcorp.com
177. PharmaSeq, Inc. www.pharmaseq.com
178. MetriGenix Corp. www.metrigenix.com
179. PamGene www.pamgene.com
180. Department of Health and Human Services, National Institutes of Health, National Human Genome Research Institute: Revolutionary genome sequencing technologies - the $1000 genome http://grants.nih.gov/grants/guide/rfa- files/RFA-HG-04-003.html (Viewed December 2005).
181. SomaLogic, Inc. www.somalogic.com
182. BioForce Nanosciences, Inc. www.bioforcenano.com
183. NanoInk, Inc. www.nanoink.net
184. Gamera Bioscience Corporation (2000). US6063589.